Pelthos Therapeutics Inc. PTHS 深 滬
已收盤 04-02 16:00:00 美东时间
20.40
-0.900
-4.23%
華盛通- 最 高21.35
- 今 開20.40
- 成交量 1.00万股
- 最 低 20.40
- 昨 收 21.30
- 總市值 6845.31万
- 52周最高 54.29
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 9.00
- 委 比 0.00%
- 總股本 335.55万
- 歷史最高 60.00
- 量 比 1.92
- 振 幅 4.46%
- 歷史最低 4.50
- 每 手 1
- 風險率 7.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye diseaseCT2000 is a lead pipeline asset of
03-31 20:31
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics Inc. has initiated a Phase 1b/2a clinical trial to evaluate CT2000, a NaV1.7 inhibitor, as a potential treatment for acute and chronic ocular pain associated with dry eye disease. CT2000, a lead asset of Pelthos subsidiary Channel Therapeutics, has shown promise in preclinical studies targeting eye pain caused by conditions like severe dry eye disease. The trial, conducted in Australia, will assess safety and efficacy in pati...
03-31 12:30
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the analyst consensus estimate of $(4.13) by 66.34 percent. This is a 115.36 percent decrease over losses of $(3.19) per share
03-19 18:33
Pelthos Q4 net loss widens to USD 21.66 million as ZELSUVMI net product revenue rises 28% to USD 9.09 million
Pelthos Q4 net loss widens to USD 21.66 million as ZELSUVMI net product revenue rises 28% to USD 9.09 million Pelthos published a press release reporting Q4 and FY 2025 financial results. Q4 net product revenues were USD 9.09 million, up 28% quarter over quarter. Q4 operating loss narrowed to USD 12
03-19 18:30
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Pelthos Therapeutics will report Q4 and full-year 2025 financial results on March 19, 2026, followed by a conference call at 8:00 a.m. ET. Details include dial-in numbers (1-877-451-6152 for U.S., 1-201-389-0879 for international) and passcode 13758894. A webcast will also be available at [link]. The company focuses on therapeutic products for skin infections, including ZELSUVMI™, Xepi®, and Xeglyze®.
03-09 12:30
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
